Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P F Schellhammer

Showing results (191-200 of 215) with videos related to

Pageof 22
Sort By:
BJU International|June 15, 1999
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancerM F Sarosdy, P F Schellhammer, M S Soloway, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixturesG L Wright, L H Cazares, S-M Leung, et al.
The Prostate|January 19, 2000
Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia G L Wright, M L Beckett, K R Newhall, et al.
Cancer Research|January 1, 1986
Human prostate tissue antigens defined by murine monoclonal antibodiesJ J Starling, S M Sieg, M L Beckett, et al.
International Journal of Oncology|September 21, 2000
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapyL S Incognito, L H Cazares, P F Schellhammer, et al.
Urologic Oncology|January 14, 2011
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future directionH Akaza, K H Kurth, R Williams, et al.
Urology|December 1, 1996
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasiaG M Marley, M C Miller, M W Kattan, et al.
The Journal of Urology|August 1, 1995
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancerM F Sarosdy, R W deVere White, M S Soloway, et al.
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Pageof 22

Showing results (191-200 of 215) with videos related to

Sort By:
Pageof 22
BJU International|June 15, 1999
Endocrine effects, efficacy and tolerability of a 10.8-mg depot formulation of goserelin acetate administered every 13 weeks to patients with advanced prostate cancerM F Sarosdy, P F Schellhammer, M S Soloway, et al.
Prostate Cancer and Prostatic Diseases|December 24, 2002
Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixturesG L Wright, L H Cazares, S-M Leung, et al.
The Prostate|January 19, 2000
Identification of a superimmunoglobulin gene family member overexpressed in benign prostatic hyperplasia G L Wright, M L Beckett, K R Newhall, et al.
Cancer Research|January 1, 1986
Human prostate tissue antigens defined by murine monoclonal antibodiesJ J Starling, S M Sieg, M L Beckett, et al.
International Journal of Oncology|September 21, 2000
Overexpression of p53 in prostate carcinoma is associated with improved overall survival but not predictive of response to radiotherapyL S Incognito, L H Cazares, P F Schellhammer, et al.
Urologic Oncology|January 14, 2011
Intravesical chemotherapy and immunotherapy for superficial tumors Basic mechanism of action and future directionH Akaza, K H Kurth, R Williams, et al.
Urology|December 1, 1996
Free and complexed prostate-specific antigen serum ratios to predict probability of primary prostate cancer and benign prostatic hyperplasiaG M Marley, M C Miller, M W Kattan, et al.
The Journal of Urology|August 1, 1995
Results of a multicenter trial using the BTA test to monitor for and diagnose recurrent bladder cancerM F Sarosdy, R W deVere White, M S Soloway, et al.
Cancer|November 15, 1996
A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Urology|September 25, 1997
Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study GroupP F Schellhammer, R Sharifi, N L Block, et al.
Pageof 22